RxDoctor Payments Data

Vikram Deshpande

Anatomic Pathology & Clinical Pathology · Boston, MANPI 1083605513

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,650 of the $20,680 with a category attached, or 90.2%. 4 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 48.7% of the total. Reporting peaked in 2021 at $10,075 and has fallen 77.7% since, to $2,250 in 2023. Among anatomic pathology & clinical pathology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,680in general payments, 2019–2025

Across 24 payments — averaging $861.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • Incyte Corporation$8K
  • Leica Microsystems Inc.$2K
  • Agios Pharmaceuticals, Inc.$19
$321,905in research payments, 2019–2025

Across 3 payments — averaging $107,302 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Agios Pharmaceuticals, Inc.$322K

What the payments were for

  • Consulting fees$18,65090%
  • Travel & lodging$1,8349%
  • Food & beverage$1961%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$20,680 in reported general payments places this provider in the 90th percentile of 196 anatomic pathology & clinical pathology providers in Massachusetts.

See all anatomic pathology & clinical pathology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$63,558
Medicare patients
600
Services billed
1,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →